The Lancet: July 18, 2013

Richard Gelber discusses results of the HERA trial comparing 2 years vs 1 year trastuzumab for HER2 positive breast cancer.

Source: Listen to The Lancet - July 18, 2013 Category: General Medicine Authors: The Lancet Source Type: podcasts